Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

19.42 -0.90 (-4.43%)
Streaming Delayed Price Updated: 10:51 AM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 639,975
Open 19.80
Bid (Size) 19.38 (2)
Ask (Size) 19.48 (1)
Prev. Close 20.32
Today's Range 18.89 - 19.90
52wk Range 2.100 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Topics Intellectual Property Retirement
Exposures Intellectual Property Pension
Why Summit Therapeutics Stock Slipped Today
Via The Motley Fool

Performance

YTD
+5.8%
+5.8%
1 Month
-6.1%
-6.1%
3 Month
+8.6%
+8.6%
6 Month
-11.3%
-11.3%
1 Year
+387.9%
+387.9%

More News

Read More
Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics
Via Benzinga
Is Summit Therapeutics a Millionaire Maker?
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Is Summit Therapeutics a Millionaire Maker?
Via The Motley Fool
This Unstoppable Biotech Stock Just Became an Even Better Buy
Via The Motley Fool
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
From Summit Therapeutics Inc.
Via Business Wire
Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?
Via Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
2 Stocks That Could Soar Again in 2025
Via The Motley Fool
Why Summit Therapeutics Stock Was Winning This Week
Via The Motley Fool
This Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This Year
Via The Motley Fool
2025 March Market Cap Showdown: Andy Cross vs. Matt Argersinger
Via The Motley Fool
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Summit Therapeutics’ Retail Chatter Explodes As Pfizer Trial Pact Drowns Out Q4 Letdown
Via Stocktwits
Palantir Extends Losses, Microsoft Slides: What's Driving Markets Monday?
Via Benzinga
Topics Stocks
Exposures US Equities
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024
From Summit Therapeutics Inc.
Via Business Wire
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
From Summit Therapeutics Inc.
Via Business Wire
Earnings Scheduled For February 24, 2025
Via Benzinga
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?
Via Benzinga
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
From Summit Therapeutics Inc.
Via Business Wire
3 Stocks That Could Trounce the Market in 2025
Via The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Jim Cramer Says AppFolio Is A 'Good One,' But Summit Therapeutics? 'Can't Go There'
Via Benzinga

Frequently Asked Questions

Is Summit Therapeutics Inc. - Common Stock publicly traded?
Yes, Summit Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Summit Therapeutics Inc. - Common Stock trade on?
Summit Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Summit Therapeutics Inc. - Common Stock?
The ticker symbol for Summit Therapeutics Inc. - Common Stock is SMMT on the Nasdaq Stock Market
What is the current price of Summit Therapeutics Inc. - Common Stock?
The current price of Summit Therapeutics Inc. - Common Stock is 19.42
When was Summit Therapeutics Inc. - Common Stock last traded?
The last trade of Summit Therapeutics Inc. - Common Stock was at 03/31/25 10:51 AM ET
What is the market capitalization of Summit Therapeutics Inc. - Common Stock?
The market capitalization of Summit Therapeutics Inc. - Common Stock is 1.89B
How many shares of Summit Therapeutics Inc. - Common Stock are outstanding?
Summit Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.